Drug intelligence / Profile preview

KRIYA-652

Development stage: Preclinical
Lead developer: Kriya Therapeutics
Modality: Gene Therapies

Overview

KRIYA-652 is an early-stage gene therapy candidate being developed by Kriya Therapeutics. As of early 2024, the program is in the discovery phase, and Kriya Therapeutics has not publicly disclosed the specific biological target or the primary therapeutic indication for this asset. KRIYA-652 is part of the company's broader portfolio of genetic medicines, which leverages an integrated platform for vector engineering and high-scale manufacturing to address diseases with significant unmet needs.

Beyond the preview

Go deeper on KRIYA-652.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRIYA-652.

Explore the full profile